Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Oral Doses of Linagliptin in Type 2 Diabetes
NCT02183415Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2005
- Primary completion
- Jan 2006
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of linagliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Assessment of tolerability by investigator at Day 50, Incidence of adverse events up to 50 days and 1 more. Started Aug 2005; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02183415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183415.